Opportunity Information: Apply for PAR 16 351
The National Institutes of Health (NIH) is offering a Research Conference Grant (R13) opportunity titled "Conference for Early Stage HIV/AIDS Vaccine Researchers (R13)" under funding opportunity number PAR-16-351. This is a discretionary grant in the health category (CFDA 93.351) intended to support the planning and delivery of intensive workshops, conferences, or meetings focused specifically on helping early stage HIV/AIDS vaccine researchers move their work from preclinical studies in nonhuman primates (NHPs) toward human clinical trials. Rather than funding bench research directly, the grant is designed to fund a structured convening where participants can learn, compare approaches, and receive practical guidance from more experienced investigators and other subject-matter experts involved in vaccine development.
The central purpose of the supported meeting(s) is to strengthen the pipeline of early career researchers working on HIV vaccines by addressing both the scientific and professional development challenges that can slow progress from animal model results to trial-ready clinical strategies. On the scientific side, the FOA emphasizes the need for conference content that helps researchers understand how to design and interpret preclinical work in ways that are truly informative for human vaccine development. A major focus is on translating findings from NHP challenge studies into decisions relevant for human trials, including how to evaluate which immune responses matter, how to compare candidate approaches, and how to frame preclinical endpoints so they map more cleanly onto clinical objectives.
The FOA also signals specific topic areas that should be incorporated into the agenda. These include critical aspects of human vaccine development such as statistical considerations (for example, study design, powering, interpretation of correlates, and avoiding common analytical pitfalls), host genetics, and other methodological issues that affect how confidently preclinical signals can be carried forward into human testing. Another required emphasis is on helping participants build milestone-driven, goal-oriented projects, meaning the meeting should encourage researchers to plan work in a way that is measurable, time-bound, and aligned with decision points that inform whether and how a vaccine concept should advance.
In addition to technical training, NIH clearly wants these meetings to develop the broader skill set that early stage investigators need to succeed and remain in the field. The FOA highlights professional growth areas including networking (building collaborations and mentoring relationships), grantsmanship (improving competitiveness for future funding through stronger proposals and strategy), and work-life balance (addressing sustainability and career longevity). The idea is to create an environment where early stage researchers can get concrete advice not only on the science of vaccine translation but also on the practical realities of building a stable, productive research career in a highly demanding area.
Eligibility is broad across U.S.-based organizations that commonly host scientific meetings. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations both with and without 501(c)(3) status (as long as they are not institutions of higher education in the latter categories). The FOA also explicitly notes additional eligible applicant types that include several categories of minority-serving institutions and other designated entities, such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and U.S. territories or possessions. At the same time, the opportunity is limited to domestic applicants: non-U.S. (foreign) institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by NIH policy are not allowed.
Key funding and timing details included in the source information indicate an award ceiling of $100,000, with an original closing date of September 6, 2016, and a creation date of June 30, 2016. Overall, this FOA is aimed at accelerating the readiness and effectiveness of early stage HIV vaccine researchers by funding a focused convening that combines high-value technical content on NHP-to-human translation with career-building support that helps investigators remain productive and competitive as they progress toward clinical impact.Apply for PAR 16 351
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Conference for Early Stage HIV/AIDS Vaccine Researchers (R13)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.351.
- This funding opportunity was created on 2016-06-30.
- Applicants must submit their applications by 2016-09-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Conference for Early Stage HIV/AIDS Vaccine Researchers (R13) - PAR-16-351
What is this NIH funding opportunity?
This opportunity is a National Institutes of Health (NIH) Research Conference Grant (R13) titled "Conference for Early Stage HIV/AIDS Vaccine Researchers (R13)" under funding opportunity number PAR-16-351. It supports the planning and delivery of intensive workshops, conferences, or meetings focused on early stage HIV/AIDS vaccine researchers.
What is the main goal of the R13 conference supported by this FOA?
The central goal is to strengthen the pipeline of early career HIV/AIDS vaccine researchers by funding a structured convening where participants can learn from experienced investigators and subject-matter experts and get practical guidance on moving work from preclinical studies in nonhuman primates (NHPs) toward human clinical trials.
Does this grant fund bench research or lab experiments?
No. Based on the information provided, this R13 is designed to fund a conference or meeting (a structured convening), not to directly fund bench research activities.
What kinds of events can be supported with this grant?
The grant is intended to support the planning and delivery of intensive workshops, conferences, or meetings. The emphasis is on a structured agenda that helps early stage researchers address both scientific and professional development challenges relevant to HIV vaccine development.
Who is the intended audience for the supported meeting(s)?
The meeting(s) are intended specifically for early stage HIV/AIDS vaccine researchers, with content and structure designed to help them progress from NHP-based preclinical research toward trial-ready strategies for human clinical studies.
What scientific transition is this conference especially focused on?
The focus is on translating preclinical findings in nonhuman primates (including NHP challenge study results) into decisions and strategies that are relevant for human vaccine development and human clinical trials.
What scientific topics does the FOA emphasize for the conference agenda?
The FOA emphasizes conference content that helps participants design and interpret preclinical work so it is informative for human vaccine development. A major focus area is translating NHP challenge study findings into trial-relevant decisions, including understanding which immune responses matter, comparing candidate approaches, and framing preclinical endpoints so they map more cleanly onto clinical objectives.
Are statistical considerations expected to be included in the conference content?
Yes. The FOA signals that statistical considerations should be incorporated, including topics such as study design, powering, interpretation of correlates, and avoiding common analytical pitfalls.
Does the FOA call out host genetics as a topic area?
Yes. Host genetics is specifically listed among the topic areas that should be incorporated into the agenda.
What does the FOA mean by “milestone-driven, goal-oriented projects”?
Based on the provided description, the meeting should encourage early stage researchers to plan their work in a way that is measurable and time-bound, aligned with decision points that inform whether and how a vaccine concept should advance toward human testing.
Is professional development a required or expected component of the meeting(s)?
Professional development is clearly emphasized. In addition to technical training, NIH wants the meeting(s) to help early stage investigators build broader skills needed to succeed and remain in the field.
What professional development areas are highlighted in the FOA?
The FOA highlights networking (building collaborations and mentoring relationships), grantsmanship (improving competitiveness for future funding through stronger proposals and strategy), and work-life balance (supporting sustainability and career longevity).
Why does NIH emphasize networking in this conference?
The stated intent is to help early stage researchers build collaborations and mentoring relationships that support scientific progress and career development in the HIV vaccine field.
Why does NIH emphasize grantsmanship in this conference?
The FOA frames grantsmanship as a way to improve competitiveness for future funding by strengthening proposals and overall funding strategy, which supports career stability and continued progress in vaccine research.
Why does NIH include work-life balance as part of the conference focus?
The FOA explicitly links work-life balance to sustainability and career longevity, aiming to help early stage investigators remain productive and stay in a demanding research area over the long term.
Who is eligible to apply for this R13 grant?
Eligibility is broad across U.S.-based organizations that commonly host scientific meetings. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations (with or without 501(c)(3) status, as long as those nonprofits are not institutions of higher education in the latter categories).
Are minority-serving institutions specifically listed as eligible?
Yes. The FOA explicitly notes eligibility for several designated categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and U.S. territories or possessions.
Can foreign (non-U.S.) institutions apply?
No. The opportunity is limited to domestic applicants. Non-U.S. (foreign) institutions are not eligible to apply.
Are non-domestic components of U.S. organizations allowed to apply?
No. The FOA indicates that non-domestic components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this opportunity?
No. The FOA states that foreign components, as defined by NIH policy, are not allowed.
What is the CFDA number and category for this opportunity?
The opportunity is in the health category and is associated with CFDA 93.351.
How much funding is available per award?
Based on the information provided, the award ceiling is $100,000.
What are the key dates listed for this FOA?
The creation date is June 30, 2016, and the original closing date is September 6, 2016.
What outcomes is NIH trying to achieve through this conference support?
The FOA aims to accelerate the readiness and effectiveness of early stage HIV vaccine researchers by supporting a focused convening that combines technical content on NHP-to-human translation with career-building support that helps investigators stay productive and competitive as they move toward clinical impact.
What makes this conference different from a general scientific meeting?
Based on the provided description, the conference is designed to be intensive and practical, with a structured focus on the specific transition from NHP preclinical studies to human clinical trials, while also addressing professional development barriers that can slow or derail early career progress.
What kinds of methodological issues are expected to be addressed?
The FOA mentions methodological issues that affect how confidently preclinical signals can be carried forward into human testing, and it specifically calls out statistics-related topics and host genetics among the areas to be included.
How does the FOA describe the role of experienced investigators and experts?
The meeting is intended to provide participants with practical guidance from more experienced investigators and other subject-matter experts involved in vaccine development, helping early stage researchers compare approaches and make more informed translational decisions.
What part of HIV vaccine development is the conference meant to strengthen?
It is meant to strengthen the early career pipeline and to improve the ability of early stage investigators to convert preclinical insights (particularly from NHP studies) into clinical strategies that are better aligned with human trial objectives.
Browse more opportunities from the same category: Health
Next opportunity: “South African University-based Technical Assistance Aimed at Improving the quality of HIV/AIDS and related services in the Republic of South Africa under the United States Presidents Emergency Plan for AIDS Relief (PEPFAR)”.
Previous opportunity: Office of Elementary and Secondary Education (OESE): Innovation and Early Learning Programs: Education Innovation and Research (EIR) Program Early-Phase Grants Assistance Listing Number 84.411C
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 351
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 351) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50) Apply for PAR 16 354 Funding Number: PAR 16 354 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| NIA Program Project Applications (P01) Apply for PAR 16 358 Funding Number: PAR 16 358 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Revision and Resubmission Program Project Applications (P01) Apply for PAR 16 359 Funding Number: PAR 16 359 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition for Cooperative Agreements to Support Navigators in Federally-facilitated and State Partnership Marketplaces Apply for CA NAV 16 001 Funding Number: CA NAV 16 001 Agency: CMS-Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| Research Initiative for Scientific Enhancement (RISE) (R25) Apply for PAR 16 361 Funding Number: PAR 16 361 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Small Research Grants for Secondary Analysis of FaceBase Data (R03) Apply for PAR 16 362 Funding Number: PAR 16 362 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Resource-Related Research Projects for Development of Animal Models and Related Materials (R24) Apply for PAR 16 369 Funding Number: PAR 16 369 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of the Gabriella Miller Kids First Pediatric Data Resource Center (U2C) Apply for RFA RM 16 010 Funding Number: RFA RM 16 010 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Phenotypic and Functional Characterization of ApoE2 to Inform Translation Strategies for Aging-Related Conditions (R21) Apply for PAR 16 371 Funding Number: PAR 16 371 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Phenotypic and Functional Characterization of ApoE2 to Inform Translation Strategies for Aging-Related Conditions (R01) Apply for PAR 16 370 Funding Number: PAR 16 370 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) Apply for PA 16 373 Funding Number: PA 16 373 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Small Grants on Primary Immunodeficiency Diseases (R03) Apply for PA 16 372 Funding Number: PA 16 372 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Predictors and Determinants of Age-Related Changes in Resiliencies to Physical Stressors in Humans (UH2/UH3) Apply for RFA AG 17 014 Funding Number: RFA AG 17 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| T1 Translational Research on Aging: Small Business Innovation Awards (R43/R44) Apply for PAR 16 375 Funding Number: PAR 16 375 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| T2 Translational Research on Aging: Small Business Innovation Awards (R43/R44) Apply for PAR 16 376 Funding Number: PAR 16 376 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1) Apply for RFA HL 17 009 Funding Number: RFA HL 17 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data and Modeling Coordination Center for the NHLBI's Precision Interventions for Severe and/or Exacerbation-Prone Asthma (PrecISE) Network (U24) Apply for RFA HL 17 010 Funding Number: RFA HL 17 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Innovations for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33) Apply for RFA AR 17 009 Funding Number: RFA AR 17 009 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (X02) Apply for PAR 16 382 Funding Number: PAR 16 382 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (R61/R33) Apply for RFA AR 17 008 Funding Number: RFA AR 17 008 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 351", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.